8-K: Processa Pharmaceuticals Appoints Russell Skibsted as New Chief Financial Officer

Processa Pharmaceuticals has appointed Russell Skibsted as its new Chief Financial Officer, effective July 16, 2024, succeeding James Stanker who is retiring.

Summary

• Processa Pharmaceuticals has appointed Russell Skibsted as its new Chief Financial Officer, effective July 16, 2024.
• Mr. Skibsted brings nearly 30 years of experience in the pharmaceutical industry, including expertise in financial management, global business development, capital raises, investor relations, and operations.
• His previous roles include CFO positions at Alimera Sciences, Rockwell Medical, and BioTime, among others.
• Mr. Skibsted will receive an annual base salary of $400,000, with a potential $50,000 increase upon achieving certain goals.
• He is also eligible for a target bonus of 35% of his base compensation and has been awarded 28,000 restricted stock units (RSUs) that vest upon achieving certain goals.
• James Stanker, the previous CFO, resigned on July 15, 2024, and will remain as a part-time employee to ensure a smooth transition.

Sentiment

Score: 7

Explanation: The document reflects a positive change with the appointment of an experienced CFO, but also acknowledges the inherent risks and uncertainties of the business. The transition is well-managed, which is a positive sign.

Positives

• The appointment of Russell Skibsted brings significant financial and industry experience to Processa Pharmaceuticals.
• Mr. Skibsted's experience includes capital raises, which could be beneficial for the company's future funding needs.
• The smooth transition is supported by the previous CFO, James Stanker, remaining in an advisory role.
• The compensation package for the new CFO includes performance-based incentives, aligning his interests with the company's success.

Risks

• The company's future performance is subject to risks and uncertainties, as detailed in their SEC filings.
• The achievement of goals related to the CFO's salary increase and RSU vesting is not guaranteed.
• The company's forward-looking statements are subject to change based on various factors.

Future Outlook

The company's future performance is subject to risks and uncertainties, and actual results may differ materially from forward-looking statements. The company does not undertake any obligation to update or revise these statements.

Management Comments

• George Ng, Chief Executive Officer, stated that Russell Skibsted's experience makes him an ideal fit for Processa.
• George Ng thanked James Stanker for his six years of service and leadership.

Industry Context

The appointment of a new CFO with extensive experience in the pharmaceutical industry is a common occurrence for companies in this sector, especially those in the clinical stage. This move is likely aimed at strengthening the company's financial position and supporting its growth plans.

Comparison to Industry Standards

• The compensation package for the new CFO, including base salary, bonus potential, and equity awards, is generally in line with industry standards for similar roles in publicly traded pharmaceutical companies.
• Russell Skibsted's experience at companies like Alimera Sciences, Rockwell Medical, and BioTime is comparable to the experience of CFOs at other clinical-stage pharmaceutical companies.
• The transition plan, with the outgoing CFO remaining in an advisory role, is a common practice to ensure continuity and knowledge transfer.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO as a positive development.
• Employees may experience a smooth transition with the previous CFO remaining in an advisory role.
• The company's financial stability and growth prospects could be positively impacted by the new CFO's expertise.

Next Steps

• Russell Skibsted will assume his duties as Chief Financial Officer.
• James Stanker will continue to support the company in an advisory role during the transition.
• The company will continue to advance its pipeline through the clinic.

Key Dates

Keywords

Chief Financial Officer, CFO, pharmaceuticals, executive appointment, financial management, capital markets, Processa Pharmaceuticals, Russell Skibsted, James Stanker